<DOC>
	<DOCNO>NCT02591095</DOCNO>
	<brief_summary>ABT-263 single agent woman platinum resistant/refractory recurrent ovarian cancer .</brief_summary>
	<brief_title>A Study ABT-263 Single Agent Women With Platinum Resistant/Refractory Recurrent Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Navitoclax</mesh_term>
	<criteria>Woman older 18 year Subjects Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 Histologically and/or cytologically document high grade serous epithelial cancer ovarian , fallopian tube peritoneum Platinum resistant ovarian cancer define relapse within 6 month platinum base chemotherapy OR platinum refractory ovarian cancer define progress platinum base chemotherapy ( excepted refractory patient first line ) Subjects receive least 2 prior line treatment include platinum regimen Subjects willing able comply protocol study procedure include willingness undergo tumor biopsy therapy screen There limitation prior number therapy Patients must document disease progression Subjects measurable disease accord Response Evaluation Criteria Solid Tumors ( RECIST ) v1.1 Adequate bone marrow , renal hepatic function per local laboratory reference range follow : • Absolute Neutrophil Count ≥ 1500/ mm3 Platelets ≥ 150,000 / mm3 Hemoglobin ≥ 9.0 g/dL Renal function : Serum creatinine ≤1.2mg/dL calculate creatinine clearance ≥ 60mL/min AST/ALT ≤ 3.0× upper limit normal ( ULN ) ; [ Subjects liver metastasis may AST , ALP , ALT le equal 5.0 X ULN ] Bilirubin ≤ 1.25×ULN Coagulation : aPTT PT exceed 1.2 × ULN LVEF &gt; 50 % echocardiograms MUGA Patients must give write informed consent Patient 's refusal impossibility perform biopsy relapse disease Bowel occlusive syndrome gastrointestinal disorder allow oral medication malabsorption Patients platinum refractory disease first line Received radioimmunotherapy within 6 month 1st dose study drug Received steroid therapy antineoplastic intent within 7 day 1st dose study drug ( Inhaled steroid asthma , topical steroid , replacement/stress corticosteroid , corticosteroid take premedication allow ) Consumption grapefruit grapefruit product within 3 day prior first dose study drug Patient receiving treatment strong CYP3A4 inhibitor inducer ( Appendix A ) Positive HIV VHC Predisposing condition/currently exhibit sign bleed Currently receive anticoagulation therapy , exception lowdose anticoagulation medication prophylaxis Received aspirin within 7 day start dose study drug Active peptic ulcer disease / potentially hemorrhagic esophagitis/gastritis Active immune thrombocytopenic purpura , autoimmune hemolytic anemia history refractory platelet transfusion ( within 1 year 1st dose study drug ) Uncontrolled cardiac , renal , neurologic , psychiatric , endocrinologic , metabolic , immunologic , hepatic disease , active systemic fungal infection ; diagnosis fever neutropenia within 1 week study drug administration A evidence current/active malignancy ovarian cancer Pregnant lactate woman</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>